Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes [PubMed record]
CrossRef Visceral obesity as a risk factor for colorectal adenoma occurrence in surveillance colonoscopy Jong Pil Im, Donghee Kim, Su Jin Chung, Eun Hyo Jin, Yoo Min Han, Min Jung Park, Ji Hyun Song, Sun Young Yang, Young Sun Kim, Jeong Yoon Yim, Seon Hee Lim, Joo Sung Kim Gastrointestinal Endoscopy.2018
These doses are intended to optimize the therapeutic effect of semaglutide without approaching the levels associated with toxicity
By mimicking both of these hormones, tirzepatide is more powerful than single-hormone GLP-1 medications
We dont want to be feeding our babies an appetite suppresant